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Abstract 
Previously, we showed three differentially sulfated forms of chondroitin sulfate proteoglycans (CSPG) associated with senile 
plaques, astrocytes and neurofibrillary tangles in Alzheimer's disease. Here, monoclonal antibodies were used to demonstrate 
CSPGs in other neurodegenerative diseases. CSPGs were found associated with inclusions of Parkinson's, diffuse Lewy body, 
Pick's diseases, and progressive supranuclear palsy. Reacting astrocytes in each of these neurodegenrative diseases and 
Huntington's disease showed immunoreactivity for CSPG. CSPG distribution in a variety of neurodegenerative diseases suggests 
that similar mechanisms may be involved in the accumulation of proteoglycans in a number of filamentous inclusions. 
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Several neurological conditions are characterized by 
intraneuronal, filamentous inclusions. The neuronal in-
clusions of Alzheimer's, Parkinson's, Pick's, diffuse 
Lewy body (DLB) diseases, and progressive supranu-
clear palsy (PSP), are principally composed of cy-
toskeletal components and share many common epi-
topes [6-10,18,20,22]. The clinical manifestations of 
the diseases, neuronal populations affected, and the 
morphology of each inclusion are distinct. It is not 
known whether similar, fundamental processes are in-
volved in the formation of neuronal inclusions, or if 
different types of inclusions arise through separate 
mechanisms. 
Certain proteoglycans have been associated with 
different diseases. Proteoglycans are highly anionic 
macromolecules that are usually found associated with 
the extracellular matrix [13-15,31] where they have 
been shown to play roles in cell adhesion and prolifera-
tion. Proteoglycans consist of a core protein with one 
or more glycosaminoglycan side chains typically at-
tached to a serine residue. Proteoglycans vary in the 
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composition of the core protein, the number and type 
of glycosaminoglycan chains and sulfate content. Hep-
aran sulfate proteoglycans (HSPG) are found in sys-
temic amyloidoses [12] as well as in the senile plaques 
and neurofibrillary tangles (NFTs) of Alzheimer's dis-
ease and Down's syndrome [19,24,25,26]' Previously, 
we found HSPG by demonstrating heparinase-sensitive 
bFGF binding sites in the inclusions of several neu-
rodegenerative diseases, including Pick's and Parkin-
son's diseases and PSP. However, diffuse Lewy bodies 
lacked bFGF-binding sites. [17] 
Chondroitin sulfate proteoglycans (CSPGs) can in-
hibit neurite outgrowth in vivo and in vitro [2,27]. 
CSPGs accumulate at injury sites in the central ner-
vous system [1,16,21]' During injury to the CNS, C-6S 
CSPG is associated with reacting astrocytes and is 
particularly inhibitory to neurite outgrowth [16]. 
Whether astrocytes produce a specific proteoglycan 
core protein during injury, or simply alter the usual 
sulfation pattern is unknown. 
Since CSPGs containing all three sulfation states of 
chondroitin were shown to be associated with senile 
plaques and NFTs of Alzheimer's disease [5], it seemed 
likely, as in the case of HSPG, that CSPGs might also 
be present in inclusions of other neurodegenerative 
diseases. In this immunocytochemical study, we 
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Fig. 1. Chondroitin sulfate immunoreactivity in Lewy bodies of 
Parkinson's disease. Substantia nigra neuron containing multiple 
Lewy bodies positive for (C-4S; panel A, arrowheads). Note typical 
rim-like staining. Lewy bodies were also seen with a homogeneous, 
pale staining (C-6S; panel S, arrowhead). !3ar = 25 p.m. 
demonstrate CSPG in a variety of inclusions and react-
ing astrocytes associated with neurodegenerative dis-
eases. Our study suggests that the inclusion-related 
cytoskeletal changes may be part of a larger program of 
structural reorganization which includes proteoglycans. 
Tissue sections from the brains tern of 5 cases of 
Parkinson's disease (ages 53-70) and from the frontal 
Table I 
or temporal cortex of 4 cases of OLB disease (ages 
75-95) were examined for the presence of CSPG in 
Lewy bodies. In addition, the pons of 4 cases of PSP 
(ages 59-83), and frontal and temporal cortex of 2 
cases of Pick's disease (ages 62, 68) were examined for 
the association of CSPG with these other neuronal 
inclusions. The caudate and putamen were examined 
from 2 cases of Huntington's chorea (ages 57, 61). Five 
control cases were also examined (57-83). All tissue 
was fixed in buffered formalin and embedded in paraf-
fin prior to sectioning at 6 ,urn. 
lmmunostaining was performed by the peroxidase 
anti-peroxidase method with 3'3'diaminobenzidine as 
the co-substrate [29]. To detect CSPGs, three mono-
clonal antibodies each raised to different sulfation 
states of chondroitin were used [4]. The three antibod-
ies recognize the stubs of chondroitin 6-sulfate, chon-
droitin 4-sulfate, or unsulfated chondroitin, respec-
tively, after chondroitinase digestion. Tissue sections 
were incubated with chondroitinase ABC [30] (Sigma) 
at 1 U jml in Tris-acetate buffer (pH 8) for 2 h at 37°C 
or overnight at 20°C followed by overnight incubation 
at 4°C with antibody. Omission of the chondroitinase 
enzyme, substitution with heparinase and heparitinase 
[17] treatments, or omission of the primary antibody 
were used as controls. Antisera to T or ubiquitin were 
used in adjacent sections to aid in identification of the 
inclusions. Antisera to glial fibrilary acidic protein 
(GFAP) was used to identify astrocytes. 
The distribution of CSPGs in the different neurode-
generative diseases is summarized in Table 1. Lewy 
bodies of Parkinson's disease found in pigmented neu-
rons of the substantia nigra were immunostained for 
unsulfated chondroitin (C-OS), chondroitin 4-sulfate 
(C-4S) and chondroitin 6-sulfate (C-6S). Most Lewy 
bodies had rim-like staining with less intense staining 
of the core (Fig. lA). Some Lewy bodies were stained 
uniformly and appeared more pale (Fig. IB). 
lntraneuronal Pick bodies showed immunoreactivity 
for C-OS and C-6S, whereas C-4S immunoreactivity was 
confined to the cytoplasm surrounding Pick bodies 
(Fig. 2A). C-OS immunoreactivity was substantially 
weaker than C-6S and may indicate less of the unsul-
fated antigen. 
Chondroitin sulfate proteoglycans are found in the disease specific inclusions of a variety of neurodegenerative diseases 
Disorder Structure C-OS C-4S C-6S 
Alzheimer's disease Senile plaques and NITs + + + 
Progressive supranuclear palsy NITs + + + 
Pick's disease Pick bodies + +* + 
Parkinson's disease Lewy bodies + + + 
Diffuse Lewy body disease Lewy bodies + + + 
Unsulfated chondroitin (C-OS), chondroitin 4-sulfate proteoglycan (C-4S) and chondroitin 6-sulfate (C-6S) are found as indicated. 
* The Pick body itself was unreactive for C-4, however, the cytoplasm surrounding the Pick body was positive. Chondroitin 4-sulfate is associated 
with but not in the Pick body. 
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Lewy bodies of DLB disease, which also have a 
cortical distribution, contained all three forms of chon-
droitin. These inclusions were identified as intracellu-
lar and juxtanuclear (Fig. 2B). The DLB disease inclu-
sions had a reticular staining pattern. Interestingly, 
some DLBD inclusions were seen that lacked CSPG 
immunoreactivity, others were somewhat immunoreac-
tive, while many were intensely immunoreactive. This 
pattern was the same for all three forms of CSPG. 
Progressive supranuclear palsy was also examined. 
NFTs of PSP also contained C-OS, C-4S, and C-6S. 
Many large neurons contained CSPG apparently asso-
ciated with fibrils inside the cell (Fig. 2C). C-OS im-
munoreactivity was substantially weaker than C-4S and 
C-6S, which may indicate fewer unsulfated gly-
cosaminoglycan chains per proteoglycan core protein. 
Astrocytic reaction could be found in each of the 
cases examined. These astrocytes showed C-4S and 
C-6S immunoreactivity. Of the cases examined, the 
Pick's cases showed the most extensive gliosis, as con-
firmed with antisera to GFAP. The Pick's cases also 
had the most intense and greatest number of CSPG-
positive astrocytes (Fig. 3A). The cases of DLB disease 
had the least number of CSPG-positive, reacting astro-
cytes. In Parkinson's disease and PSP (Fig. 3B) the 
CSPG-positive astrocytes were seen among inclusion-
bearing neurons. In the caudate and putamen of Hunt-
ington's disease, astrocytes positive for CSPG im-
munoreactivity were found (Fig. 3C) while the cortex of 
these cases showed relatively few. In controls, only a 
small number of GFAP-positive astrocytes displayed 
CSPG immunoreactivity. 
In all cases, chondroitinase digestion was required 
for antibody binding [4,5]. Antibody specificity was 
demonstrated by a lack of immunoreactivity following 
heparinase and heparitinase digestion or if chondroiti-
nase treatment was absent. 
In this study we demonstrated CSPGs associated 
with intraneuronal inclusions of several neurodegener-
ative diseases. Inclusions of Pick's, DLB, and Parkin-
son's diseases, and from PSP are associated with all 
three sulfation states of chondroitin. In addition, astro-
cytes contain C-4S and C-6S in these diseases as well 
as Huntington's disease. Huntington's disease cases 
were examined because this disease is characterized by 
astrogliosis and neuronal loss but a lack of inclusions. 
In a previous study, we demonstrated that glial cells 
accumulate and secrete CSPGs in response to A{3 as a 
substrate [3]. In this study, we found CSPG associated 
with astrocytes in neurodegenerative diseases not char-
acterized by A{3 deposits. Therefore, while A{3 may 
play a key role in CSPG deposition around senile 
plaques in Alzheimer's disease, it is unlikely to be the 
sole initiator for CSPG accumulation in neurodegener-
ative diseases. 
Extracellular proteoglycans have been shown to play 
roles in cell proliferation, migration, and cell adhesion. 
HSPGs and CSPGs are found primarily in the extracel-
Fig. 2. Pick bodies usually showed weak immunoreactivity for chondroitin (arrowheads), however, the cytoplasm surrounding the Pick body was 
more intensely stained (C-4S; panel A, small arrowheads). Chondroitin immunoreactivity in diffuse Lewy bodies had a reticular staining pattern 
(C-4S; panel B, arrowhead). NFTs in progressive supranuclear palsy showed chondroitin immunoreactivity associated with fibrils within the 
cytoplasm (C-6S; panel C, arrowhead). Bar = 25 JLm. 
208 D.A. DeWitt et al. / Brain Research 656 (]994) 205-209 
Fig. 3. Reacting astrocytes show CSPG immunoreactivity. Astrocytes 
in gliosis of Pick's disease (C-6S; panel A). Some reactive astrocytes 
are seen in close proximity to neurons with inclusions. An astrocyte 
(small arrow) is located next to a PSP NFT (C-6S; panel B, large 
arrow). Astrocytes in the caudate of a Huntington's patient (C-6S; 
panel C). Bar = 20 /Lm. 
lular matrix, but have been found intracellularly 
[15,19,28]. HSPG and now CSPG have been shown to 
be a common component of neuronal inclusions. Ex-
cessive internal accumulation of proteoglycans could 
hinder normal intracellular transport, potentially in-
ducing accumulation of many other proteins. 
Proteoglycans may play an active role in the forma-
tion of these inclusions. Since the inclusions are com-
prised cytoskeletal components, one possibility is that 
the cytoskeletal proteins are interacting with the pro-
teoglycans to form the inclusion. These inclusions are 
resistant to proteases. Proteoglycans have been shown 
to alter normal proteolytic degradation of proteins 
such as bFGF [23] and Af3 [11]. In addition, systemic 
amyloidoses, which contain proteoglycans, are resistant 
to proteolysis. The accumulation of proteoglycans in 
the presence of abnormal cytoskeletal components 
could prevent the efficient degradation and removal of 
those abnormal fibrils, allowing them to persist. While 
different types of inclusions occur in distinct neuronal 
populations and consist of various proteins, proteogly-
cans appear to be a common component. Proteoglycan 
protection from proteolysis could be a fundamental 
mechanism leading to inclusion formation. 
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